NFKB1 and glioblastoma: Senescent cells have not been directly identified in GBM, however, treatment with Temozolomide in GBM cell lines has revealed the activation of senescent features, including increased P21 expression, DNA damage, activation of the NF-κB pathway and elevated SASP release such as IL-6 and IL-8 [183].